Uric acid may signal kidney trouble in prediabetes
NCT ID NCT07199205
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether high uric acid levels can help predict if kidney disease gets worse in people with prediabetes. Researchers will follow 150 adults with prediabetes and early-stage kidney disease to track changes in kidney function over time. The goal is to find a simple way to identify those at higher risk, so doctors can step in earlier.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2025
An estimate. Start dates often move.
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population divided into three groups: The first group includes individuals at high risk of chronic kidney disease (prediabetic patient s) The second group comprises individuals diagnosed with early ckd stage A1,A2,A3 The third group serves as the control group and includes participants with normal renal function
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: * Adults aged 18 years and older. * Diagnosed with prediabetes, defined according to the American Diabetes - - - - Association (ADA) criteria (fasting plasma glucose 100-125 mg/dL, HbA1c 5.7-6.4%, or 2-hour plasma glucose 140-199 mg/dL after oral glucose tolerance test). * Baseline estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m² (CKD stages 1-2). * Willingness to provide informed consent and comply with study procedures. Exclusion criteria: * Diagnosis of diabetes mellitus (fasting plasma glucose ≥126 mg/dL, HbA1c ≥6.5%). * Established CKD stage 3 or higher (eGFR \<60 mL/min/1.73 m²). * History of gout or current use of uric acid-lowering therapy (e.g., allopurinol, febuxostat) or acute gout. * Use of medications known to significantly affect uric acid levels (e.g., thiazide diuretics, high-dose aspirin). * Pregnancy or lactation. * Presence of severe comorbid conditions (e.g., malignancy, active infection, advanced liver disease).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CKD progression are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.